MOLM-13

MOLM-13 is a human leukemia cell line derived from the peripheral blood of a patient with acute myeloid leukemia(AML), FAB M5a, at relapse. The immunotype of MOLM-13 includes CD34⁺, CD13⁻, CD14⁻, CD15⁺, CD33⁺, CD3⁻, CD4⁺, cy CD68⁺, HLA-DR⁻. After stimulated by INF-γ alone, or in combination with TNF-α, MOLM-13 can differentiate into macrophage-like morphology and express upregulated myelomonocyte-associated antigens. Internal tandem duplication of the receptor tyrosine kinase FLT3 gene is a unique feature of MOLM-13, compared to other leukemia cell lines. MOLM-13 can be cultured in RPMI1640 supplemented with 10% FBS, and the split ratio used to passage cells is 1:2 or 1:3 every 2-3 days.

 

Why choose MOLM-13 from AcceGen?

The cell quality of MOLM-13 from AcceGen is evaluated with various tests and analyses. Cell morphology and cell viability are examined to ensure MOLM-13 with optimal characteristics. The growth performance of MOLM-13 is also tested to gauge the stability of this cell line. Notably, MOLM-13 is conducted under culture conditions without the use of antibiotics and antimycotics, highlighting the cells’ inherent resilience. Lastly, we rigorously screened for the absence of HIV-1, HIV-2, HBV, HCV, HTLV-1, and HTLV-2, as well as microbial contaminants such as fungi, bacteria, and mycoplasma. These meticulous assessments ensure the reliability and safety of MOLM-13 for various applications.